The hypoglycemia-prevention effect of sensor-augmented pump therapy with predictive low glucose management in Japanese patients with type 1 diabetes mellitus: a short-term study.

The predictive low glucose management (PLGM) system was introduced in March 2018 in Japan. Although there are some reports demonstrating the benefit of PLGM in preventing hypoglycemia, no data are currently available in Japanese patients with type 1 diabetes mellitus (T1DM). The aim of the present study is to evaluate the effect of PLGM with sensor-augmented pump therapy in the prevention of hypoglycemia in Japanese patients. We included 16 patients with T1DM who used the MiniMed The area under the curve (AUC) of hypoglycemia of < 70 mg/dL was lowered from 0.42 ± 0.43 mg/dL day to 0.18 ± 0.18 mg/dL day ( The hypoglycemia avoidance rate was comparable to those in previous reports. In addition, we demonstrated that PLGM can markedly suppress severe hypoglycemia without deteriorating glycemic control in Japanese T1DM patients. It is necessary to further investigate the effective use of the PLGM feature such as establishing a lower limit and the timing of resumption.

Informations de copyright

© The Japan Diabetes Society 2019.

Déclaration de conflit d'intérêts

Conflict of interestAuthor Atsuhito T. received lecture fees from Medtronic Japan, Sanofi and Eli Lilly. Author Jun W. received lecture fees from Astellas, Astra Zeneca, Boeringer Ingelheim Japan, Daiichi Sankyo, MSD, Novartis, Tanabe Mitsubishi and Taisho Toyama, and received research funding from Bayer, Baxter, Chugai, Dainippon Sumitomo, Kyowa Hakko Kirin, MSD, Novartis, Novo Nordisk, Ono, Takeda, Tanabe Mitsubishi and Teijin. Other authors declare that they have no conflict of interest associated with this research.